Atara Biotherapeutics, Inc. - Special Call Transcript
Good morning, ladies and gentlemen, and welcome to the Atara Biotherapeutics ATA188 Data Conference Call. My name is Liz, and I will be your operator for today's call. I'd now like to turn the conference over to your host, Eric Hyllengren, Vice President of Investor Relations and Finance. You may now begin.
Thank you, Liz. Good morning, everyone, and welcome to the Atara ATA188 data conference call. Earlier this morning, we issued a press release reporting exciting data from our ongoing Phase Ia clinical trial of ATA188 presented at ECTRIMS in an e-poster this morning. This press release and the slides we will be presenting during this call are available in the investors and media section of atarabio.com. I'm joined today on the call by Dr. Pascal Touchon, President and Chief Executive Officer; Dr. Jakob Dupont, Executive Vice President and Global Head of Research and Development; Dr. AJ Joshi, Chief Medical Officer; and Utpal Koppikar, Chief Financial Officer.
I'd like to remind
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |